The deal, which has an enterprise value of £3bn, is the first one by Cinven’s seventh fund
US buyout firm KKR has agreed to sell the life sciences company LGC Group to a consortium jointly led by private equity groups Cinven and Astorg.
The deal has an enterprise value of approximately £3bn, a personal familiar with the transaction told Private Equity News. KKR has made about three times its money since the acquisition of the company from Bridgepoint in 2015, the person said.
The private equity firms declined to comment on the financial terms of the transaction.
The investment is the first deal struck by Cinven’s seventh fund, closed in May after raising €10bn to invest in European buyouts and selective North American opportunities.
LGC, which provides measurement and testing solutions, reported a revenue of £448m in 2019, with organic revenue growth accelerating to 10% per annum since 2016. Under KKR’s ownership, the company made 15 acquisitions in the last five years.
London-based Cinven and Paris-based Astorg said they identified LGC as an attractive investment opportunity because of its “strong performance and organic growth” and they saw “significant future development opportunities”.
Established in 1842, LGC employs more than 3,200 people, is headquartered in the UK and serves almost 50,000 laboratories worldwide from its global office network spanning 22 countries across five continents.
“Cinven’s investment in LGC was identified as a result of the healthcare sector team’s focus on the life sciences space,” said Supraj Rajagopalan, partner at Cinven. “LGC is exposed to a wide range of diversified and fast-growing end markets across the Standards and Genomics sectors and we look forward to working with the highly experienced management team to continue investing in strengthening and broadening LGC’s global footprint and portfolio of leading, high-quality products.”
The deal is still subject to regulatory approvals.
Source: Private Equity News
Can’t stop reading? Read more
THL Partners to acquire Headlands Research from KKR amid clinical trials boom
THL Partners to acquire Headlands Research from KKR amid clinical trials boom THL Partners has agreed to acquire a majority stake in US clinical trial operator Headlands Research from KKR, in a transaction valued at about $600m, according to sources familiar with the...
Monroe Capital adds Antares veteran Todd Davis to boost origination platform
Monroe Capital adds Antares veteran Todd Davis to boost origination platform Monroe Capital has hired Todd Davis as Director on its direct originations team, strengthening its coverage of the Northeast US market. Based in New York, Davis will be responsible for...
Searchlight invests $400m in Chord Music Partners, owner of ZZ Top and Ellie Goulding catalogues
Searchlight invests $400m in Chord Music Partners, owner of ZZ Top and Ellie Goulding catalogues Searchlight Capital is committing $400m to Chord Music Partners, the music rights company backed by Universal Music Group (UMG) and Dundee Partners, according to a SkyNews...